NCT04404790 - Antiplatelet Thrombolysin (Anfibatide) Phase 1 Clinical Trial in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2020

Primary Completion Date

March 31, 2021

Study Completion Date

May 31, 2021

Conditions

Antiplatelet Drug

Interventions

DRUG

Anfibatide 5 IU/60kg

5 IU/60kg IV administration of Anfibatide with 5 minutes

DRUG

Anfibatide 5 IU/60kg +0.002 IU/kg/h

5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours

DRUG

Anfibatide 5 IU/60kg +0.004 IU/kg/h

5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours

DRUG

Anfibatide 5 IU/60kg +0.008 IU/kg/h

5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours

DRUG

Anfibatide 7 IU/60kg

7 IU/60kg IV administration of Anfibatide with 5 minutes

DRUG

Anfibatide 7 IU/60kg +0.002 IU/kg/h

7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours

DRUG

Anfibatide 7 IU/60kg +0.004 IU/kg/h

7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours

DRUG

Anfibatide 7 IU/60kg +0.008 IU/kg/h

7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours

Trial Locations (1)

Bengbu Medical College First Hospital, Bengbu